NKTR Nektar Therapeutics
Nektar Therapeutics (NKTR) Hedge Fund Activity
This view isolates hedge funds from the broader institutional ownership shown on the Institutional tab. A pension fund tracking an index may have no view on a stock; when a hedge fund builds or exits a position, that decision can carry information. This page measures those changes. Positions as of June 30, 2026.
Based on quarterly 13F long-equity filings. Changes compare reported quarter-end positions; filings can be reported up to 45 days later and do not represent a fund's complete exposure.
Most significant moves
Ranked by conviction, not size — how much of the fund's own book the position represents, how far it moved, and what kind of fund made it.
| Fund | Action | Shares changed | Change | Est. value | Portfolio wt. | Score |
|---|---|---|---|---|---|---|
| Two Seas Capital Event | Increased | +1.13M | +57.8% | $79.1M | 8.2% | 68 |
| Deep Track Capital Growth Healthcare | New | +300.0K | — | $20.9M | 0.3% | 66 |
| Vestal Point Capital Growth Healthcare | Increased | +715.0K | +250.9% | $49.9M | 1.6% | 65 |
| Braidwell Growth Healthcare | Increased | +250.9K | +112.7% | $17.5M | 1.3% | 61 |
| RENAISSANCE TECHNOLOGIES LLC Quant | Sold Out | -41.8K | -100.0% | $2.9M | 0.0% | 60 |
| Soleus Capital Management Growth Healthcare | New | +128.4K | — | $9.0M | 0.3% | 60 |
| Farallon Capital Management Event Value | Sold Out | -4.0K | -100.0% | $279.2K | 0.0% | 60 |
| Point72 Asset Management, L.P. | Sold Out | -13.4K | -100.0% | $932.9K | 0.0% | 59 |
| Balyasny Asset Management L.P. | Sold Out | -35.9K | -100.0% | $2.5M | 0.0% | 59 |
| Alyeska Investment Group, L.P. | Sold Out | -50.0K | -100.0% | $3.5M | 0.0% | 58 |
Most significant buyers
By move score, not size.
- Two Seas Capital
- Deep Track Capital
- Vestal Point Capital
- Braidwell
- Soleus Capital Management
Most significant sellers
By move score, not size.
- RENAISSANCE TECHNOLOGIES LLC
- Farallon Capital Management
- Point72 Asset Management, L.P.
- Balyasny Asset Management L.P.
- Alyeska Investment Group, L.P.
Hedge fund positions
| Fund | Tier | Shares | Previous | Change | Change % | Portfolio wt. | Action | Score |
|---|---|---|---|---|---|---|---|---|
| Two Seas Capital | 2 | 3.1M | 2.0M | +1.13M | +57.8% | 8.2% | Increased | 68 |
| Deep Track Capital | 1 | 300.0K | 0 | +300.0K | — | 0.3% | New | 66 |
| Vestal Point Capital | 1 | 1.0M | 285.0K | +715.0K | +250.9% | 1.6% | Increased | 65 |
| Braidwell | 2 | 473.6K | 222.7K | +250.9K | +112.7% | 1.3% | Increased | 61 |
| RENAISSANCE TECHNOLOGIES LLC | 1 | 0 | 41.8K | -41.8K | -100.0% | 0.0% | Sold Out | 60 |
| Soleus Capital Management | 2 | 128.4K | 0 | +128.4K | — | 0.3% | New | 60 |
| Farallon Capital Management | 1 | 0 | 4.0K | -4.0K | -100.0% | 0.0% | Sold Out | 60 |
| Point72 Asset Management, L.P. | 1 | 0 | 13.4K | -13.4K | -100.0% | 0.0% | Sold Out | 59 |
| Balyasny Asset Management L.P. | 2 | 0 | 35.9K | -35.9K | -100.0% | 0.0% | Sold Out | 59 |
| Alyeska Investment Group, L.P. | 2 | 0 | 50.0K | -50.0K | -100.0% | 0.0% | Sold Out | 58 |
| Biotechnology Value Fund | 1 | 2.4M | 2.6M | -168.5K | -6.6% | 4.3% | Reduced | 58 |
| Ghisallo Capital Management | 2 | 32.0K | 0 | +32.0K | — | 0.1% | New | 57 |
| Tudor Investment Corporation | 2 | 0 | 15.0K | -15.0K | -100.0% | 0.0% | Sold Out | 56 |
| Jain Global | 3 | 0 | 36.2K | -36.2K | -100.0% | 0.0% | Sold Out | 54 |
| Man Group | 3 | 0 | 19.4K | -19.4K | -100.0% | 0.0% | Sold Out | 54 |
| Readystate Asset Management | 3 | 85.1K | 0 | +85.1K | — | 0.4% | New | 53 |
| Hudson Bay Capital Management | 3 | 0 | 10.3K | -10.3K | -100.0% | 0.0% | Sold Out | 53 |
| Capstone Investment Advisors | 3 | 6.9K | 0 | +6.9K | — | 0.0% | New | 53 |
| AQR Capital Management | 3 | 22.5K | 0 | +22.5K | — | 0.0% | New | 53 |
| MARSHALL WACE, LLP | 2 | 3.3K | 140.6K | -137.3K | -97.7% | 0.0% | Reduced | 52 |
| Walleye Capital | 3 | 0 | 12.9K | -12.9K | -100.0% | 0.0% | Sold Out | 51 |
| Schonfeld Strategic Advisors | 3 | 0 | 8.1K | -8.1K | -100.0% | 0.0% | Sold Out | 51 |
| Aquatic Capital Management | 4 | 0 | 57.0K | -57.0K | -100.0% | 0.0% | Sold Out | 51 |
| OrbiMed Advisors | 2 | 465.3K | 275.0K | +190.3K | +69.2% | 0.6% | Increased | 50 |
| Y-Intercept | 4 | 0 | 26.5K | -26.5K | -100.0% | 0.0% | Sold Out | 50 |
| Squarepoint Ops LLC | 2 | 5.8K | 107.4K | -101.6K | -94.6% | 0.0% | Reduced | 49 |
| LMR Partners | 3 | 100.0K | 48.3K | +51.7K | +107.1% | 0.1% | Increased | 49 |
| CenterBook Partners | 4 | 0 | 7.4K | -7.4K | -100.0% | 0.0% | Sold Out | 49 |
| ExodusPoint Capital Management | 3 | 58.5K | 20.5K | +38.1K | +186.0% | 0.0% | Increased | 48 |
| CITADEL ADVISORS LLC | 1 | 159.7K | 513.5K | -353.8K | -68.9% | 0.0% | Reduced | 48 |
| Quantbot Technologies | 4 | 0 | 417 | -417 | -100.0% | 0.0% | Sold Out | 45 |
| Qube Research & Technologies Ltd | 2 | 130.5K | 390.7K | -260.2K | -66.6% | 0.0% | Reduced | 45 |
| ADAR1 Capital Management | 3 | 244.2K | 161.3K | +82.9K | +51.4% | 0.9% | Increased | 41 |
| Armistice Capital | 3 | 724.0K | 578.0K | +146.0K | +25.3% | 1.4% | Increased | 39 |
| TWO SIGMA INVESTMENTS, LP | 2 | 1.2M | 930.7K | +271.3K | +29.1% | 0.1% | Increased | 37 |
| Brevan Howard Capital Management | 3 | 21.9K | 48.5K | -26.6K | -54.8% | 0.0% | Reduced | 34 |
| MILLENNIUM MANAGEMENT LLC | 2 | 478.1K | 404.3K | +73.8K | +18.3% | 0.0% | Increased | 33 |
| Voleon Capital Management | 3 | 40.8K | 65.1K | -24.2K | -37.2% | 0.1% | Reduced | 32 |
| Engineers Gate | 4 | 19.2K | 12.3K | +6.9K | +55.9% | 0.0% | Increased | 31 |
| Winton Group | 4 | 25.9K | 16.9K | +9.0K | +53.2% | 0.1% | Increased | 31 |
| Woodline Partners LP | 2 | 470.9K | 415.3K | +55.5K | +13.4% | 0.1% | Increased | 29 |
| Quinn Opportunity Partners | 4 | 153.1K | 179.2K | -26.2K | -14.6% | 0.5% | Reduced | 27 |
| Trexquant Investment | 3 | 56.7K | 55.5K | +1.2K | +2.2% | 0.0% | Increased | 20 |
Every fund above opens. Subscribers can see any manager's whole portfolio — every position, its weight, and what they bought, trimmed and exited last quarter.
Sign in or subscribeHedge funds are identified from their 13F filings, which are due 45 days after quarter end and cover long U.S.-listed equity positions only. A fund's short book never appears, so a reduced position can mean a changed view or a changed hedge — the filing doesn't say which.